XML 66 R55.htm IDEA: XBRL DOCUMENT v3.25.2
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Dec. 29, 2023
Jun. 28, 2023
Feb. 28, 2023
May 17, 2021
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Interest income         $ 105,787 $ 102,030 $ 197,113 $ 207,795      
Outstanding principal balance         $ 5,208,924   $ 5,208,924   $ 4,108,913 $ 4,606,227  
Common stock share issued         29,804,299   29,804,299   23,689,135    
Accounts receivable balance         $ 15,455,787   $ 15,455,787   $ 13,478,263    
Prepaid expenses and other current assets - related party         1,637,553   1,637,553   1,310,388    
Revenue         14,745,702 13,206,717 28,458,230 27,791,190      
Loans receivable - related party current portion         615,592   615,592   614,473    
Loans receivable - related party noncurrent portion         3,051,171   3,051,171   2,876,523    
Grigorios Siokas [Member]                      
Outstanding principal balance         0   0   6,194    
Foreign curreny translation             850        
Cana Holdings Laboratories Holding Limited [Member]                      
Secured promissory note     $ 4,457,520                
Description related to interest on principal     Interest on the Principal Amount under this Note shall accrue at a rate equal to Five Percent (5%) plus 1 month LIBOR per annum (5.47% as of December 31, 2023)                
DOC Pharma S.A. [Member]                      
Interest income         49,653 51,528 $ 99,307 103,584      
Interest rate             5.50%        
Prepayment relates to purchases of inventory             $ 3,600,000        
Loan term             10 years        
Maturity date             Dec. 31, 2032        
Accounts payable and accrued expenses - related party         498,988   $ 498,988   249,768    
Prepaid balance         4,273,089   4,273,089        
Accounts receivable - related party         2,606,798   2,606,798   2,295,706    
Other expenses                     $ 7,599,545
Cumulative allowance for doubtful accounts             1,600,000        
Prepaid expenses and other current assets - related party         4,273,089   $ 4,273,089   3,284,052    
Pieces per product             1,000 pieces        
Purchased of additional licenses                 525,461 734,921  
Impairment charge                 160,947    
Revenue         130,362 384,321 $ 263,757 520,721      
Current portion of Royalty Agreement         412,000   412,000        
Non-current portion of Royalty Agreement         2,059,750   2,059,750        
Inventroy purchase         300,208 189,048 658,019 425,656      
Purchase of branded pharmaceuticals $ 3,539,840 $ 1,965,600                  
Description of research and development       The total cost of this project will be €1,425,000 plus VAT and will be done over three phases as follows: Design & Development (€725,000); Control and Product Manufacturing (€250,000) and Clinical Study and Research (€450,000). SkyPharm has bought a total of as of 81 licenses at value of €554,500 ($593,204) which is 38.91% of the total cost, as of December 31, 2022              
Loans receivable - related party current portion         815,706   815,706   517,550    
Loans receivable - related party noncurrent portion         3,204,580   3,204,580   2,898,280    
Monthly basis instalments             37,150        
DOC Pharma S.A. [Member] | Inventories Related Agreement [Member]                      
Inventroy purchase         228,534 66,295 443,039 137,027      
Dimitrios Goulielmos [Member]                      
Outstanding principal balance         10,200   10,200   10,558    
Foreign curreny translation             1,447        
Panagiotis Kozaris [Member]                      
Shares owned                   $ 51,159 $ 143,056
Prepaid expenses         194,215   194,215   194,215    
Maria Kozari [Member]                      
Accounts receivable balance         1,347,235   1,347,235   1,183,429    
Cumulative allowance for doubtful accounts             909,881   $ 735,000    
Net sales         100,870 86,678 217,565 196,607      
George Terzis [Member]                      
Unpaid salaries and bonuses         296,947   296,947        
Unpaid salaries and bonuses dues         228,000   228,000        
Kanarogloy & Sia Epe [Member]                      
Accounts payable and accrued expenses - related party         16,588   16,588        
Basotho Investment Limited [Member]                      
General and administrative expenses         $ 0 $ 0 $ 30,900 $ 61,800      
Common stock share issued         120,000   120,000